Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.
about
Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).Drug Development of Therapeutic Monoclonal Antibodies.Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients.Gota et al. on their article "the pharmacokinetics of Reditux™, a biosimilar of rituximab".
P2860
Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Influence of tumour burden on ...... non-metastatic breast cancer.
@ast
Influence of tumour burden on ...... non-metastatic breast cancer.
@en
type
label
Influence of tumour burden on ...... non-metastatic breast cancer.
@ast
Influence of tumour burden on ...... non-metastatic breast cancer.
@en
prefLabel
Influence of tumour burden on ...... non-metastatic breast cancer.
@ast
Influence of tumour burden on ...... non-metastatic breast cancer.
@en
P2093
P2860
P356
P1476
Influence of tumour burden on ...... e non-metastatic breast cancer
@en
P2093
David Ternant
François Lokiec
Guillemette Bernadou
Jean-Louis Merlin
Mario Campone
Marta Jimenez
Monica Arnedos
Thomas Bachelot
Valérie Gouilleux-Gruart
Véronique Diéras
P2860
P304
P356
10.1111/BCP.12875
P407
P577
2016-03-07T00:00:00Z